Menu

Cystic Fibrosis (CF)

Cystic Fibrosis (CF) is the most common genetically determined, early onset and still lethal disease. CF affects approximately one in 2,500 newborns in Germany. With improvements in symptomatic therapies and standardized CF medical care, the median survival age of CF patients in Germany has risen to approximately 40 years. However, despite recent breakthroughs in disease-modifying therapies for a small subgroup of patients with specific CF geno types, there are currently no therapies available to the majority of patients that target CF lung disease at its root. The overall aim of the DZL CF research program is to advance the current understanding of the pathogenesis of CF lung disease and to use this knowledge to improve CF diagnostics, to develop more sensitive tools for monitoring of disease activity, and novel strategies for the effective prevention and therapy of CF lung disease.

Scientific Coordinators of the Disease Area

Prof. Dr. Marcus Mall (BIH)
Prof. Dr. Burkhard Tümmler (BREATH)

Administrative Coordinator of the Disease Area

Dr. Birgit Teucher (TLRC)

Participating DZL Partner Sites

ARCN, BREATH, TLRC, UGMLC

News about Cystic Fibrosis (CF)

13. November 2020

Lung inflammation in Cystic Fibrosis – a novel method paves the way to an improved understanding and treatment

A team of DZL researchers has developed a novel tool to measure the activity of two proteins implicated in lung inflammation in cystic fibrosis.
Read More
21. August 2020

Breakthrough In The Therapy Of Cystic Fibrosis

EMA, the European Medicines Agency, approved Kaftrio, a new triple-combination therapy for the treatment of cystic fibrosis.
Read More
3. June 2019

New Gene-Delivery Systems Raise Hope for Patients with Cystic Fibrosis

Although research is advancing with great strides, the life expectancy of people with cystic fibrosis (CF) is still significantly reduced.
Read More
All Cystic Fibrosis (CF) news
chevron-down